Egypt Oncology Therapeutics Market Report 2022 to 2030

Egypt Oncology Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Egypt Oncology Therapeutics Market will reach a value of $1.1 Bn from $0.51 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030. The Oncology Therapeutics Market in Egypt is dominated by a few domestic pharmaceutical companies such as Pharco, EIPICO, and Amoun Pharmaceutical. The Oncology Therapeutics Market in Egypt is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Egypt Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10EGPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Vishwa Modhia

Buy Now

Egypt Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Egypt Oncology Therapeutics Market will reach a value of $1.1 Bn from $0.51 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030.

Egypt is a lower middle-income, developing country in North Africa that borders the Red Sea and the Mediterranean Sea. The number of new cancer cases in Egypt in 2020 was 1,34,632. In 2020, there were 89,042 cancer deaths. Noncommunicable diseases account for 85 % of deaths in Egypt, with cancer being the second most prevalent cause of death (14 %) behind cardiovascular disorders (46 %).

The National Cancer Institute (NCI) is responsible for cancer prevention and control in Egypt through designing and sustaining integrated quality programmes in patient treatment, research, education, and prevention. NCI hospital with 550 beds was built in stages. It is presently the Middle East's largest cancer hospital. Many efforts have been done in oncology throughout the years to enhance cancer prevention, screening, and early diagnosis in Egypt, all of which contribute to better health care. Egypt's government spent 4.4% of its GDP on healthcare in 2020.

Egypt Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Egypt approved the Universal Health Insurance (UHI) bill in 2018 to attain universal health coverage as part of Transforming Egypt's Healthcare System Project. The Egyptian Ministry of Health and Population recently released a treatment map for malignant tumours in adults and children, emphasising that early discovery aids in illness treatment. When compared to other lower-middle-income countries, Egypt has the highest overall number of oncologists and cancer centres in the Middle East and Africa, yet one of the lowest health expenditures per capita. These aspects could boost Egypt Oncology Therapeutics Market.

Market Restraints

Egypt does not have a national screening programme, and the great majority of patients present with either locally advanced or metastatic disease. Target therapy, for example, is only available in insurance-covered private sectors in the Levant and Egypt, whereas immunotherapy is more difficult to obtain. Egypt still faces major disease management challenges today, owing to its rising population, limited resources, and lack of infection control procedures. These factors may deter new entrants into the Egypt Oncology Therapeutics Market.

Competitive Landscape

Key Players

Pharco Pharmaceuticals: Pharco Pharmaceuticals is an Egyptian pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs and targeted therapies. The company has a strong focus on research and development and has several innovative cancer drugs that are currently in clinical development
Amoun Pharmaceutical Company: Amoun Pharmaceutical Company is an Egyptian pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs and targeted therapies. The company has a strong presence in Egypt and other countries in the Middle East
EIPICO: EIPICO is an Egyptian pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs, targeted therapies, and biosimilars
Minapharm: Minapharm is an Egyptian pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs, targeted therapies, and biologics

Notable Recent Deals

December 2022: According to Olfat Ghorab, a Ministry of Health and Population official, Egypt plans to develop 76 high-value pharmaceuticals, including those for cancer therapy, by the end of 2023. Ghorab stated that the proposal will secure such pharmaceuticals at half the cost and create opportunities for graduates of pharmacology and scientific colleges. She also stated that the production will be done in collaboration with American and French companies.

June 2022: Egypt's Minister of Higher Education and Scientific Research and Acting Minister of Health and Population, Khaled Abdel Ghaffar, has announced the launch of a sub-initiative for the early detection of lung and colon cancers as part of the presidential initiative "100 Million Health." This occurred during Abdel Ghaffar's appraisal of the development activities of the African Center for Women's Health in Alexandria. He also looked into the governorate's other medical facilities, such as Al-Amiriya General Hospital, Ras Al-Tin General Hospital, and Gamal Abdel Nasser Hospital.

Healthcare Policies and Reimbursement Scenarios

In Egypt, the administrative body liable for the endorsement and guidelines of helpful items, including disease therapeutics, is the Egyptian Health Regulatory Agency (ANVISA). In the public medical care framework, the expense of malignant growth therapies, including disease therapeutics, is covered by the Egyptian Unified Health System (SUS). The SUS is a public program that gives free medical services administrations to Egyptian residents and qualified occupants.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

By 2030, it is anticipated that the Egypt Oncology Therapeutics market will reach a value of $1.1 Bn from $0.51 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030.

In Egypt, the administrative body liable for the endorsement and guidelines of helpful items, including disease therapeutics, is the Egyptian Health Regulatory Agency (ANVISA).

The Oncology Therapeutics Market in Egypt is dominated by a few domestic pharmaceutical companies such as Pharco, EIPICO, and Amoun Pharmaceutical.